{"id":"W2980178765","doi":"10.14309/01.ajg.0000592716.59064.e9","title":"795 Real World Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naïve Ulcerative Colitis and Crohn's Disease Patients: Results From the EVOLVE Study","year":2019,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Takeda (Canada)","funders":"","keywords":"Medicine; Vedolizumab; Infliximab; Adalimumab; Ulcerative colitis; Discontinuation; Internal medicine; Hazard ratio; Adverse effect; Incidence (geometry); Golimumab; Certolizumab pegol; Inflammatory bowel disease; Crohn's disease; Surgery; Confidence interval; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004757568,0.0001933083,0.0006939618,0.0004454971,0.0002629183,0.001002271,0.0003124505,0.0003934749,0.001258872],"category_scores_gemma":[0.006606593,0.0001427402,0.0009485901,0.0009220075,0.0002879677,0.000404506,0.0005658479,0.000429159,0.0002663278],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006188652,"about_ca_system_score_gemma":0.0008508522,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002353883,"about_ca_topic_score_gemma":0.002483826,"domain_scores_codex":[0.9969008,0.001401571,0.0004638528,0.0002955553,0.0007841964,0.0001540237],"domain_scores_gemma":[0.9905103,0.002461046,0.005136518,0.0005338257,0.0008734442,0.0004849059],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01940621,0.0005781213,0.9533389,0.0004015876,0.001318902,0.0001121699,0.0001623144,0.0004109436,0.0003383349,0.0001066567,0.000730602,0.02309524],"study_design_scores_gemma":[0.002254385,0.007846009,0.9830736,0.000160507,0.0009835353,0.0004672436,0.0001574009,0.0007158033,0.0004169533,0.00007483765,0.003828634,0.00002111398],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916418,0.003256361,0.0002295018,0.00009981789,0.0000105291,0.0001392652,0.002927608,0.000008804601,0.00168625],"genre_scores_gemma":[0.99362,0.0008465836,0.0002461406,0.000118466,0.00003835794,0.0001062088,0.004675691,0.000003675266,0.0003449161],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004757568,"threshold_uncertainty_score":0.02516073,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005638200429910815,"score_gpt":0.2308133125755644,"score_spread":0.2251751121456536,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}